As one of the chief players in the automated cell therapy manufacturing space grapples with a recent setback, another is ...

It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Xiogenix, an innovator in cell and gene therapy downstream process automation, today ...

With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies have emerged in recent years on a mission to simplify production for the ...

When most people think of cancer care, they rarely associate it with what goes on behind the scenes to create life-saving treatments. For starters, developing cell and gene therapies is pricey, and ...

Blood centers have the donors, resources and community footprint drug sponsors need to solve supply chain issues around cell and gene therapies.

Addressing the operational challenges of making autologous cell therapies remains a major challenge for industry.

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...